Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (1490) clinical trials

People with lymphoma are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

People with lymphoma are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

The purpose of this study is to assess the safety, tolerability, and efficacy when combining INCB024360 and Nivolumab in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)

Phase N/A

The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 (closed) and Phase 2 (open to enrollment)

Phase N/A

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BAY 1251152 in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).

Phase

The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with MF-CTCL who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 1 year from the date of signed informed consent (enrollment) until end of study. Continuation in the ...

Phase N/A

The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP) has on Diffuse Large B Cell Lymphoma.

Phase N/A

The purpose of this study is to test any good and bad effects of several different study drugs or drug combinations, each of which targets specific genetic changes found in some cancers.

Phase N/A

Patients should be in need of and fit for immunochemotherapy and should not be resistant to rituximab (resistance defined as lack of response, or progression within 6 months of the last course of treatment with a rituximab containing regimen). This study will be composed of two parts: Safety run-in and ...

Phase

The study will be divided into two parts: a "dose-escalation part" to evaluate safety profile and to explore the Maximum tolerated dose (MTD) and an "expansion part" to evaluate further the safety and tumor response profile of BAY1862864 Injection at the selected dose.

Phase